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Constitutive activityWe analyzed the kinetic and spatial patterns characterizing activation of the MAP kinases ERK 1 and 2 (ERK1/2)
by the three α1-adrenoceptor (α1-AR) subtypes in HEK293 cells and the contribution of two different pathways
to ERK1/2 phosphorylation: protein kinase C (PKC)-dependent ERK1/2 activation and internalization-dependent
ERK1/2 activation. The different pathways of phenylephrine induced ERK phosphorylation were determined by
western blot, using the PKC inhibitor Ro 31-8425, the receptor internalization inhibitor concanavalin A and the
siRNA targeting β-arrestin 2. Receptor internalization properties were studied using CypHer5 technology and
VSV-G epitope-tagged receptors. Activation of α1A- and α1B-ARs by phenylephrine elicited rapid ERK1/2 phos-
phorylation that was directed to the nucleus and inhibited by Ro 31-8425. Concomitant with phenylephrine
induced receptor internalization α1A-AR, but not α1B-AR, produced a maintained and PKC-independent ERK
phosphorylation, which was restricted to the cytosol and inhibited by β-arrestin 2 knockdown or concanavalin
A treatment. α1D-AR displayed constitutive ERK phosphorylation, which was reduced by incubation with
prazosin or the selective α1D antagonist BMY7378. Following activation by phenylephrine, α1D-AR elicited
rapid, transient ERK1/2 phosphorylation that was restricted to the cytosol and not inhibited by Ro 31-8425.
Internalization of the α1D-AR subtype was not observed via CypHer5 technology. The three α1-AR subtypes
present different spatio-temporal patterns of receptor internalization, and only α1A-AR stimulation translates
to a late, sustained ERK1/2 phosphorylation that is restricted to the cytosol and dependent on β-arrestin 2
mediated internalization.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The α1-adrenoceptors (α1-ARs) have been extensively investigated
with regard to their pharmacology and structure–function relationship.
In contrast, less is known about their regulatory properties, and the
trafﬁcking and protein interactions involved in these processes. They
are heptahelical transmembrane proteins that belong to the G protein-
coupled receptor (GPCR) superfamily. Upon agonist binding, α1-ARs
stimulate activation and dissociation of the α and βγ subunits of Gq/11
proteins [1], and promote PKC activation [2], as well as an increase ofnoceptor; AT1AR, angiotensin re-
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l rights reserved.intracellular IP3 and calcium content [3,4]. Extracellular signal-
regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) acti-
vation promotedby the differentα1-AR subtypes has also been detected
[5,6]. Termination of GPCR signaling is triggered by the phosphorylation
of the agonist-occupied receptor by G-protein-coupled receptor-kinases
(GRKs) and the second-messenger-dependent protein kinases PKA and
PKC [5,7], promoting high afﬁnity binding of cytoplasmatic β-arrestins
to the receptor, resulting in its desensitization and endocytosis [8].
Three differentα1-AR subtypes (α1A,α1B andα1D) have been cloned
and exhibit differences in amino acid sequence and antagonist binding
afﬁnities [9,10]. Different cellular localization is also exhibited by the
three subtypes: α1B-AR is primarily expressed on the cell surface [11],
α1A-AR is detected not only on the cell surface, but also intracellularly
[12]. In contrast, α1D-AR appears to be localized perinuclearly and pro-
duces ERK1/2 activation in the absence of agonists [11]. This α1D-AR
constitutive activity has also been measured by a spontaneous increase
in the resting tone [13–16] and calcium and IP3 accumulation [17,18] in
rat aorta, where the main α1-AR subtype is α1D.
An increasing number of studies indicate that the α1-AR subtypes
display striking differences in their internalization properties and, al-
though controversial, it has been suggested thatwhileα1B-AR undergoes
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disagree and suggest that α1A-AR also internalizes upon agonist activa-
tion, although to a lesser extent than theα1B-AR, and thatα1D-AR is con-
stitutively internalized [12,20]. It has also been suggested that α1A-AR is
located in lipid rafts under basal conditions, but exits from these rafts
following stimulation, therefore allowing endocytosis [21].
Recently, distinct models of regulation of ERK1/2 activation
over time after GPCR activation have been proposed and for many
GPCRs, it has been shown that β-arrestin recruitment and receptor-
endocytosis are implicated in ERK1/2 activation [22]. For example, angio-
tensin II activation of the AT1A receptor elicits both, a rapid (peak 2 min),
G protein-dependent, ERK1/2 activation and a delayed (peak 5–10 min)
andpersistent ERK1/2 activation, that isβ-arrestin2-dependent [23]. Sim-
ilar patterns were found for the β2-AR [24] and the parathyroid hormone
receptor [25].
To our knowledge, no coherent analysis of the temporal proﬁle of
internalization and ERK1/2 MAPK activation by the three α1-AR sub-
types is available. In the presentwork,we performed a study of the tem-
poral and spatial patterns of ERK1/2 activation after stimulation of each
human α1-AR stably expressed in HEK293 cells. We explored whether
such signals were modiﬁed by β-arrestin 2 transcriptional silencing,
by blocking receptor endocytosis with concanavalin A (ConA), and by
inhibiting PKC with a selective inhibitor. We also studied the different
properties of receptor internalization into acidic endosomes by using
CypHer5 technology [26,27] and VSV-G epitope tagged receptors to
shed light into potential differences between the α1-AR subtypes.
2. Materials and methods
2.1. Antibodies and reagents
The antibodies used included phospho-p42/44 ERK MAPK
(Thr202/ Thr204) and p42/44 ERK MAPK (Cell Signaling Technology,
Beverly, MA). CypHer5-anti-VSV-G tag antibody (PA45407), horserad-
ish peroxidase-labeled secondary antibodies and chemiluminescent re-
agents were from GE Healthcare (Amersham, Buckinghamshire, UK).
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)was pur-
chased from Panreac (Barcelona, Spain). Anti-actin antibody (A2066),
concanavalin A (ConA), phenylephrine, Ro 31-8425, prazosin, antibiotic
G418, 5-methylurapidil, BMY7378, phentolamine, ethylenediamine-
tetraacetic acid (EDTA), Nonidet™ P-40, phenylmethanesulfonyl ﬂuo-
ride (PMSF), sodium vanadate, sodium ﬂuoride, ditiothreitol and poly-
L-lysine (molecular weight 70,000–150,000) were purchased from
Sigma (Sigma, St Louis, MO).
2.2. Construction of the VSV-G-Tagged α1-AR subtypes
TheVSV-G (YTDIEMNRLGK) epitope tagwas introduced immediately
upstream of each human α1A-AR, α1B-AR and α1D-AR. The amino-
terminal primer (5′-AAAAAAAAGGATCCGCCACCATGTACACCGATATAG
AGATGAACAGGCTGGGAAAGGTGTTTCTCTCGGGAAATGC-3′) or (5′-AAA
AAAAGCTTCCACCATGTACACTGATATCGAAATGAACCGCCTGGGTAAGAA
TCCCGACCTGGACACCG-3′) or (5′-AAAAAAAGCTTCCACCATGTACACTG
ATATCGAAATGAACCGCCTGGGTAAGACTTTCCGCGATCTCCTGAGCG-3′)
was used to incorporate a VSV-G tag, a consensus Kozak sequence and
BamHI, HindIII and HindIII sites forα1A-,α1B- andα1D-AR, respectively.
Depending on the subtype used as a template, the following carboxyl
terminal reverse primer was hybridized: α1A-AR, 5′-AAAAAAAACTCG
AGCTAGACTTCCTCCCCGTTC-3′; α1B-AR, 5′AAAAAGAATTCCTAAAACTG
CCCGGGCGC-3′; and α1D-AR, 5′-AAAAAGAATTCTTAAATATCGGTCTCCC
GTAGGTTGC-3′ respectively, incorporating a XhoI site, EcoRI and
EcoRI sites downstream of the coding sequence. All the PCR fragments
were subsequently cloned into the plasmid pcDNA3 (Invitrogen,
Paisley, Renfrewshire, UK) by in-frame ligation. Construct sequences
were conﬁrmed by nucleotide sequencing.2.3. Cell culture and transfection
HEK293 cells were grown in Dulbecco's modiﬁed Eagle's minimum
essential medium (Sigma) supplemented with 10% newborn calf
serum (Gibco BRL, Gaithersburg, MD), L-glutamine 2 mM (Gibco BRL),
100 μg/ml streptomycin and 100 units/ml penicillin at 37 °C in a
humidiﬁed atmosphere of 5% CO2. Cells were transfected by electropo-
ration (300 V, 50 μs, 2 mm gap) using a Multiporator (Eppendorf
AG, Hamburg, Germany). After 48 h, cells were selected with G418
400 μg/ml to identify stably expressing clones. All the experiments
were performed at around 75% cell conﬂuence.
2.4. RNA extraction and quantitative reverse-transcription polymerase
chain reaction
RNA extraction and quantitative reverse-transcription polymerase
chain reaction was performed as previously described [28,29]. The
threshold cycle (Ct) values obtained for each gene were referenced
to GAPDH and converted into the linear form using the term 2−ΔCt
as a value directly proportional to the copy number of mRNA.
2.5. Saturation binding experiments
Intact HEK293 cells (1.25 × 105, 5 × 105 and 1 × 106) stably
transfected with each α1-AR were incubated in duplicate for 45 min
at 25 °C with [3H]prazosin in 50 mM Tris HCl (pH 7.5) in a ﬁnal vol-
ume of 1 ml. Samples were incubated with [3H]prazosin concentra-
tions ranging from 0.01 to 6 nM. The experiments were terminated
by rapid ﬁltration through ﬁberglass ﬁlters (Schleicher and Schuell,
GF 52) pre-soaked in 0.3% polyethyleneimine using a Brandel cell har-
vester (M24R). The ﬁlters were then washed three times with 4 ml of
ice cold 50 mM Tris–HCl buffer (pH 7.5), and ﬁlter bound radioactivity
was determined by liquid scintillation counting. Nonspeciﬁc binding
was measured in the presence of 10 μM phentolamine. The binding
data were analyzed by non-linear regression using Prism, version 4.0
(Graph Pad Software; San Diego, California, USA) to determine the dis-
sociation constant (Kd), and the maximum number of binding sites
(Bmax) for the saturation data. The saturation data were ﬁtted to hyper-
bolic functions (one or two sites). The best ﬁt to the one-site or two-
sites was evaluated using the F-test (P b 0.05).
2.6. β-Arrestin 2 siRNA knockdown
The expression of β-arrestin 2 was silenced using HP validated
siRNA duplexes targeting human ARRB2 (Hs_ARRB2_10 siRNA; Catalog
no. SI02776928, Qiagen). AllStars non-targeting siRNA (Catalog no.
1027284,Qiagen)wasused as negative control. The day before transfec-
tion, cells were seeded in 30 mm dishes in regular growth medium
without antibiotics and grown overnight. The day of transfection,
Lipofectamine™2000 (Invitrogen)-siRNA complexes were prepared in
Opti-MEM I reduced serummedium according tomanufacturer's proto-
col. Cells were transfected with either 50 nM β-arrestin 2 siRNAs or
non-targeting control siRNA complexes for 6 h followed by replacement
with fresh growthmedium including antibiotics. Transfected cells were
assayed 48 h post-transfection. Suppression of the target gene was
conﬁrmed by western blot.
2.7. Real-time imaging of the internalization of the α1-AR subtypes to
acidiﬁed endosomes in HEK293 cells
HEK293 cells stably expressing the N-terminal VSV-G tagged human
α1A-, α1B- and α1D-AR subtypes were plated onto poly-L-lysine coated
sterile coverslips 48 h before experimentation. Live cells were washed
three times with cold Krebs-Ringer-Hepes buffer (KRH, 120 mM NaCl,
25 mM HEPES, 4.8 mM KCl, 1.2 mM MgSO4 and 1.3 mM CaCl2 at
pH 7.4) at 4 °C and were then incubated with CypHer5E linked
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UK) at 5 μg/ml in KRH buffer at 4 °C for 1 h. After washing with KRH
buffer at 4 °C, coverslips were rapidly mounted into a ﬂow chamber
bath (Attoﬂuor, Molecular Probes; Eugene, OR), placed on the micro-
scope stage in a 95% air and 5% CO2 atmosphere at 37 °C. At this time,
cells were exposed to control pre-warmed KRH buffer or buffer
supplemented either with ConA (250 μg/ml) or prazosin (10 μM) for
30 min. After incubation with the aforementioned solutions, the zero
time was set up immediately before adding phenylephrine (100 μM)
to the imaging chamber and the system was set to acquire images at
5-min intervals for 15 min. A set of control experiments without addi-
tions was performed. A laser-scanning confocal inverted microscope
(LEICA TCS SP2 (DM-IRBE), equipped with a 60× oil HCX PL APO
(1.32 numerical aperture) objective, was used to acquire images. The
excitation wavelength was 633 nm using a helium/neon laser and the
emitted ﬂuorescence was detected with a 650 nm long pass ﬁlter.
Image processing and analysis were carried out using MetaMorph, ver-
sion 6.1r3 (Universal Imaging Corporation) and the Leica software,
v.2.61. Internalization kinetic was quantiﬁed at different times, bymea-
suring the intensity of 5 deﬁned line segments in the cytosolic region of
the cell. We calculated the normalized signal for each line segments at
each time point as Ii/I0, where I0 is the intensity taken before agonist
stimulation for each segment. For each experiment, 5–8 cells were
quantiﬁed. Data represent the mean of more than four independent
experiments.
2.8. Preparation of cellular extracts and immunoblotting
HEK293 cells on 60 × 15mm plates were starved for 4 h in
serum-free medium. Prior to stimulation with phenylephrine, cells
were treated for 30 min with ConA (250 μg/ml) or with Ro 31-8425
(1 μM) for 15 min,where indicated. After stimulation, cellswerewashed
once with cold PBS and lysed by rotating 30 min at 4 °C with 500 μl
of RIPA buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 1.5 mM
MgCl2, 0.1% SDS, 1 mM EGTA, 1% Triton-X 100 and 1% sodium
deoxycholate) containing protease inhibitor cocktail (Complete®,
Roche Applied Science) and phosphatase inhibitor cocktail (PhosSTOP®,
Roche Applied Science). Sonication with a Microson™ XL 2000 Ultra-
sonic Liquid Processor and storage at−80 °C followed. The protein con-
tent was measured by the Bradford method (Bio-Rad, Hercules CA).
15 μg of cellular extracts was incubated with SDS-sample buffer
(2% SDS, 60 mMTris buffer, 5%β-mercaptoethanol, 0.01% bromophenol
blue and 10% glycerol) at 40 °C for 30 min, separated on 10% SDS-
polyacrylamide gels and transferred to PVDF membranes for immuno-
blotting. Prior to antibody incubation, membranes were blocked in
phosphate-buffered saline with 0.1% Tween 20 (PBST) plus 3% BSA
(albumin from bovine serum, Sigma, St Louis, MO). Phospho-p42/44
MAPK (Thr202/ Thr204) and p42/44 MAPK antibodies (Cell Signaling
Technology), β-arrestin or the actin antibody (Sigma St Louis, MO)
were incubated overnight at 4 °C, 1/500 for the p42/44 MAPK and
1/2500 for actin diluted. Membranes were then washed three
times with PBST, incubated with an anti-rabbit IgG horseradish
peroxidase-conjugated secondary antibody (GE Healthcare, Amersham
Buckinghamshire, UK) at 1/2500 for 45 min at room temperature, and
was washed extensively with PBST before chemiluminescent detection
was performed using the ECL Western Blotting Detection Reagents
(GE Healthcare). Images were captured with an AutoChemi System
(uvp Bioimaging Systems. Cambridge, UK), and band intensity was
measured using LabWorks Image acquisition and Analysis (Ver. 4.6
uvp Bioimaging Systems, Cambridge, UK).
2.9. Confocal microscopy immunocytochemistry
HEK293 cells on poly-L-lysine coated 35 mm glass bottom dishes
were starved for 4 h in serum free medium prior to stimulation. After
stimulation, cells were ﬁxed with 6% formaldehyde in PBS. Fixed cellswere permeabilized with 0.01% Triton in PBS containing 2% BSA for
90 min, incubated with the phospho-p42/44 MAPK (Thr202/Thr204)
antibody (Cell Signaling Technology, 1:200) at room temperature over-
night, and repeatedly washed using PBS. Incubation of the secondary
antibody Alexa Fluor 488 goat anti-rabbit (Molecular Probes; Eugene,
OR, 1:1000) was performed for 20 min at room temperature followed
by repeated washes using PBS. Then cells were incubated with Hoechst
33342 (Molecular Probes; Eugene, OR, 1:1000) for 15 min in darkness
at room temperature on glass slides using Mowiol reagent 4-88
(Calbiochem, Darmstadt, Germany). Confocal images were obtained
on a LEICA TCS SP2 (DM-IRB) laser scanning microscope using either
the line 488 nm and emission 510–570 nm ﬁlter set for Alexa 488 or
the 352 and 364 nm excitation and emission 390–480 nm ﬁlter set for
Hoechst. A z-series of images was acquired at 2 μm steps to produce
individual z-stacks. Interaction of Hoechst and p-ERK signals at the
same z-stack was depicted in white by colocalization analysis with the
Leica software, v2.61.
2.10. Statistical analysis
The results are presented as the mean ± S.E.M. for n experiments.
A statistical analysis was performed by the two-way ANOVA or by the
Student's t-test (GraphPad Software, Inc., San Diego, CA, USA). Signif-
icance was deﬁned as P b 0.05.
3. Results
Using real-time RT-PCR, saturation radioligand binding techniques,
immunocytochemistry and ﬂuorescent ligands we conﬁrmed that the
three α1-ARs, and the corresponding VSV-G-tagged α1-ARs, were stably
expressed in the HEK293 cell lines generated (Supplemental data 1
and 2).We founddifferent expression levels of the threeα1-AR subtypes,
especially remarkable for the α1D-subtype in binding but not in PCR
assays. Considering the magnitude of the signals elicited by the agonist
and in agreement with previous works [30], we propose that this appar-
ent lower Bmax observed, could be interpreted as a lower binding of the
α1D subtype to radioligands and not as a reduced protein expression.
3.1. Subtype-speciﬁc kinetic pattern of ERK1/2 activation
ERK1/2 activation in the transfected HEK293 cells was promoted
by α1-AR stimulation by phenylephrine (PE). The ERK1/2 phosphory-
lation induced by each α1-AR subtype following addition of PE was
completely blocked in the presence of the α1-AR antagonist prazosin
(PZ) (Supplemental data 2A). Furthermore, non-transfected cells
showed no ERK1/2 phosphorylation after incubation with PE. The
effect of different PE concentrations on ERK1/2 activation resulted
in concentration-dependent responses (Supplemental data 2B) that
varied for the three subtypes with α1A displaying the lowest sensitiv-
ity (pED50 α1A-AR: 4.325 ± 0.14; pED50 α1B-AR: 6.838 ± 0.12; pED50
α1D-AR: 6.153 ± 0.16). This corresponds to previous results found
when measuring IP3 generation, contractile response or intracellular
Ca2+ increase [4,9,14,28]. We selected 100 μM PE for subsequent ex-
periments to ensure that ERK1/2 phosphorylation by all three α1-AR
subtypes was observed. This high dose of PE has also been used in
other studies where the ERK1/2 activation by α1-ARs was investigated
[11,12].
As we have previously reported different kinetic proﬁles ofα1A- and
α1D-AR responseswhen studying contractile properties of blood vessels
[13,16], we performed a spatio-temporal analysis to examine if the
same was true for α1-AR subtype activation of ERK1/2. As shown in
Fig. 1 or Supplemental data 3 and as previously described, the α1D-,
but not the α1A- or α1B-AR shows basal phosphorylation of ERK1/2
[11]. Incubation with PE of cells stably expressingα1A-AR rapidly elicits
a fast ERK1/2 activation (peak 1–5 min) followed by a slow and pro-
gressive reduction of phospho-ERK1/2, which returned to basal levels
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underwent a similar initial increase but this was transient and the
phospho-ERK1/2 levels were rapidly reduced to basal level. To deter-
mine if the α1-AR subtype proﬁles corresponded to the differential
regulation of ERK1/2 activation previously described [23,25], we
studied the early component, potentially G protein-dependent, by
blocking PKC with the inhibitor Ro 31-8425 [23], and employing the
receptor-internalization inhibitor ConA [29], which is known to inhibit
endocytosis-dependent ERK1/2 activation [30]. AlthoughDMSO0.045%,
the vehicle of Ro 31-8425, seems to impair the late (N10 min) p-ERK
signal after α1A-AR stimulation (Fig. 2A, Control), pre-treatment
with Ro 31-8425 resulted in a dramatic decrease (≈70%) in ERK1/2
activation by PE at early time periods (1–5 min). Fig. 2B shows how
pre-treatment of the α1A-AR with ConA, prior to stimulation by PE,
resulted in transient ERK1/2 activation, which rapidly decreased after
5 min of agonist treatment and returned to near the basal values after
30 min. Since some studies have revealed that in the case of ERK1/2
activation by AT1A receptor stimulation, a Gαq-coupled receptor,
beta-arrestin2 but not beta-arrestin1 mediates G protein-independent
ERK1/2 activation [23,31,32], we silenced β-arrestin 2 in cells express-
ing each α1-AR subtype (see Supplemental data 4). The kinetic proﬁle
of the ERK1/2 signal after β-arrestin 2 knock-down was similar to that
observed in the presence of ConA (Fig. 2C), the sustained ERK1/2 phos-
phorylation mediated by activation of the α1A-AR was signiﬁcantly
affected in cells transfected with β-arrestin2 siRNA.
We performed the same Ro 31-8425, ConA and β-arrestin 2 knock-
down treatments on cells expressing α1B-ARs. As Fig. 3A depicts,
pre-treatment with the PKC inhibitor blocked ERK1/2 activation by PE
over the entire 60 min period studied. In this case, pre-treatment with
ConA or β-arrestin 2 knock-down had no effect on ERK1/2 activation
by PE (Fig. 3B, C). In the HEK293 cells transfected with α1D-AR,
pre-treatment with Ro 31-8425 did not inhibit the early increased100
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phosphorylation because phospho-ERK1/2 levels were higher in the
presence of Ro 31-8425 after 10 min of PE incubation (Fig. 4A). Pre-
treatment with ConA or β-arrestin 2 siRNA did not modify ERK1/2
phosphorylation kinetics after α1D-AR activation (Fig. 4B, C).3.2. The subtype-speciﬁc distribution pattern of ERK1/2 activation
An increasing number of studies suggest a differential spatial
regulation of ERK1/2 when activated by either G protein- or
β-arrestin-dependent pathways [23,33,34]. Consensus suggests that
ERK1/2 rapidly phosphorylated via G protein-activation, is directed
to the nucleus, while ERK1/2 resulting from β-arrestin-mediated
activation and scaffolding, exclusively remains in the cytoplasm. Fig. 5A
displays confocal images depicting phospho-ERK1/2 localization before
(PE 0 min), or 5 and 30 min after PE incubation. Stimulation of α1A-AR
with PE for 5 min, resulted in an increment of phospho-ERK1/2 through-
out the cell, including the nucleus as this fraction co-localized with
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higher phospho-ERK1/2 basal levels, thus conﬁrming thatα1D-AR consti-
tutively activates ERK1/2 as found by Western blot; and secondly, acti-
vated ERK1/2 was only present in the cytosol and not in the nucleus,
even after 5 min of PE incubation when the phospho-ERK1/2 level was
maximal. Nuclear localization of phospho-ERK after 5 min of PE incuba-
tionwas assessed by co-localization analysis of the images, where p-ERKα1A-AR
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Fig. 2. The PKC inhibitor Ro 31-8425, receptor-internalization inhibitor ConA and β-arrestin2 knock-down modify the PE-induced ERK1/2 activation patterns in cells expressing
α1A-AR. 75% conﬂuent HEK293 cells stably expressing the α1A-AR subtype were serum-starved for 4 h and stimulated with PE (100 μM) at 37 °C. When indicated, cells were
incubated with A) Me2SO [Control (DMSO), 0.045%] vehicle or 1 μM Ro 31-8425 for 15 min, B) with ConA 250 μg/ml for 30 min prior to PE stimulation or C) β-arrestin2 was
knock-down. The phosphorylated ERK1/2 content in each lane was quantiﬁed by densitometry and expressed as a percentage of the maximal ERK1/2 phosphorylation in control.
Each data point represents the mean ± S.E.M. of 4–6 independent experiments. Statistics was performed by the two way ANOVA. ***P b 0.001 vs. control.
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Fig. 3. Ro 31-8425, but not ConA or β-arrestin2 knock-down modiﬁes the PE-induced ERK1/2 activation pattern in the cells expressing α1B-AR. 75% conﬂuent HEK293 cells stably
expressing the α1B-AR subtype were serum-starved for 4 h and stimulated with PE (100 μM) at 37 °C. When indicated, cells were incubated with A) Me2SO [Control (DMSO),
0.045%] vehicle or 1 μM Ro 31-8425 for 15 min, or B) with ConA 250 μg/ml 30 min prior to PE stimulation or C) β-arrestin2 was knock-down. The phosphorylated ERK1/2 content
in each lane was quantiﬁed by densitometry and expressed as a percentage of the maximal ERK1/2 phosphorylation in control. Each data point represents the mean ± S.E.M. of 3
independent experiments. Statistics was performed by the Student's t test. **P b 0.001, *P b 0.05 vs. control.
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Fig. 4. Ro 31-8425, but not ConA or β-arrestin2 knock-down modiﬁes the PE-induced ERK1/2 activation pattern in the cells transfected with α1D-AR. 75% conﬂuent HEK293 cells
stably transfected with the α1D-AR subtype were serum-starved for 4 h and stimulated with PE (100 μM) at 37 °C. When indicated, cells were incubated A) with Me2SO [Control
(DMSO), 0.045%] vehicle or 1 μMRo-31-8425 for 15 min before PE incubation, B) with ConA 250 μg/ml 30 min prior to PE stimulation or C) β-arrestin2 was knock-down. The phos-
phorylated ERK1/2 content in each lane was quantiﬁed by densitometry and expressed as a percentage of the maximal ERK1/2 phosphorylation in control. Each data point repre-
sents the mean ± S.E.M. of 3 independent experiments. Statistics was performed by the two way ANOVA Control vs. Ro 31-8425. *P b 0.05.
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2329M. Perez-Aso et al. / Biochimica et Biophysica Acta 1833 (2013) 2322–2333and Hoechst nuclear staining coexisting at the same level is depicted in
white (Fig. 5A).
To determine if the initial phospho-ERK1/2 distribution induced by
PE activation (peak 5 min)was PKC-dependent,we performed immuno-
cytochemistry experiments following incubation with the PKC inhibitor
Ro 31-8425 before PE stimulation. Although DMSO could slightly modify
p-ERK localization to thenucleus after PE 5 minwhen compared to stim-
ulus without DMSO, Fig. 5B shows confocal images demonstrating that
PKC inhibition prevented phospho-ERK1/2 translocation to the nucleus
in the α1A- and α1B-AR-transfected cells. By contrast, Ro 31-8425 had
no effect on either the phospho-ERK1/2 localization after α1D-AR activa-
tion or on the 30-min PE-induced ERK1/2 phosphorylation produced via
the α1A-AR subtype.B
A
Fig. 5. α1-AR stimulation shows a subtype-speciﬁc distribution pattern of ERK1/2 activation.
for 4 h and stimulated with PE (100 μM) for 0, 5 and 30 min at 37 °C. These were A) not pr
and vehicle (DMSO). After stimulation, cells were prepared for immunocytochemistry a
Hoechst-stain nuclei (blue) is represented by white in the overlay image. Bar scale represe3.3. Subtype-speciﬁc receptor internalization patterns
By N-terminally tagging the three α1-AR subtypes with the VSV-G
epitope and employing a CypHer-5 dye labeled anti-VSV-G antibody
that displays red ﬂuorescence only in an acidic environment [26,27],
internalization to the acidiﬁed endosomes of previously cell surface
receptors was monitored in stably transfected, live HEK293 cells.
Initially, we localized the three subtypes of α1-ARs by confocal micros-
copy as previously described [11,12] (Supplemental data 5) and veriﬁed
that the VSV-G-taggedα1-ARs activated ERK1/2 with the same kinetics
as the non tagged receptors, this is the VSV-G-α1A-AR elicits an early
and late ERK1/2 activation, while the VSV-G-α1B- and VSV-G-α1D-AR
only activate ERK1/2 after 5 min but not after 30 min (Supplemental75% conﬂuent HEK293 cells stably expressing each α1-AR subtype were serum-starved
etreated with Ro 31-8425 or B) pretreated with Ro 31-8425 15 min before PE addition
s described under the “Material and methods”. Colocalization of p-ERK (green) and
nts 10 μm.
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(Fig. 6A) and agonist-induced internalization (Fig. 6B and C) to acidic
endosomes. According to our experimental procedure, after 30 min of
incubation at 37 °Cwe can observe that the constitutive internalization
to endosomes of VSV-α1B-AR, was inhibited by ConA (Fig. 6A), an inhib-
itor of receptor-endocytosis [35–38]. The phenylephrine induced
internalization of VSV-G-α1A but not that of the VSV-α1B subtype
(Fig. 6B and C), was decreased by ConA. We were not able to detect
the internalization of the VSV-G-α1D-AR to acidiﬁed endosomes using
this approach (results not shown).4. Discussion
Some recent studies have shown that after the stimulation of GPCRs,
such as the angiotensin AT1A receptor [23], β2-AR [24] and parathyroid
hormone receptors [25], a pool of ERK1/2 that is activated by the G
protein-dependent pathway translocates into the nucleus, whereas
activated ERK1/2 that is dependent on β-arrestin-mediated receptor
endocytosis, remains in the cytoplasm [23,33,34]. In this work, we
have characterized a rapid phosphorylation of ERK1/2 that is dependentFig. 6. α1A- and α1B-AR stimulations show a subtype-speciﬁc receptor-internalization pa
VSV-G-tagged-α1A- or VSV-G-tagged-α1B-AR were incubated with the CyPher5 linked anti-V
in a ﬂow chamber bath and placed in a confocal microscope stage in a 95% air and 5%
supplemented or not supplemented with ConA (250 μg/ml) for 30 min and the constitut
added and agonist-induced internalization of α1A and α1B -ARs was quantiﬁed for 30 min (
by two way ANOVA (P b 0.05) and by Student's t-test to compare internalization at each timon α1A- and α1B-AR activation of PKC, and promotes p-ERK1/2 translo-
cation to the nucleus.
Furthermore, we have also shown thatα1A-, but notα1B-AR, elicits a
sustained activation of ERK1/2 which limits its distribution to the cyto-
plasm and which is inhibited by β-arrestin 2 knockdown and blocked
by the receptor endocytosis-inhibitor ConA, suggesting that the inter-
nalized receptor plays a functional role in this signaling process. Distinct
expression levels of α1A- and α1B-AR could be involved in the differ-
ences observed in the time-course of ERK1/2 activation. However, the
fact that response was expressed as a percentage of the maximal
response in each caseminimizes the distortion introduced by the differ-
ent expression level. In addition, conﬁrming our results, a similar
α1A-dependent activation of ERK1/2 through an endocytic pathway
has been recently evidenced in HEK293 cells [39]. Present results
show for the ﬁrst time that the biphasic ERK phosphorylation pattern
described for certain GPCRs has been attributed only to theα1A-subtype
and, what is more, that the three different α1-AR subtypes present sig-
niﬁcant differences in this regard (shown schematically in Fig. 7). Along
these lines, we have demonstrated that α1B-AR elicits a rapid, transient
ERK activation, which is PKC-dependent and delivered to the nucleus,
but did not show the β-arrestin dependent ERK phosphorylationttern and dependency on ConA. 75% conﬂuent HEK293 cells stably transfected with
SV antibody at 5 μg/ml for 1 h. After washing with the KRH buffer, cells were mounted
CO2 atmosphere at 37 °C. At this time, cells were pre-warmed with the KRH buffer
ive internalization was measured (A). At this point, phenylephrine (PE) 100 μM was
B and C respectively) as described in “Material and methods”. Statistics was performed
e. ***P b 0.001, **P b 0.01, and *P b 0.05 vs. control or PE. Bar scale represents 20 μm.
Fig. 6 (continued).
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transient ERK activation after agonist stimulation, this initial peak is
not only independent of PKC and β-arrestin, but is also conﬁned to
the cytosol, which therefore increases the complexity of the α1-AR sig-
naling network. Exactly why α1D-AR activates ERK through a distinct
pathway is an open question that needs to be investigated further.
At this point, it is interesting to note that both the α1A and α1B
receptors internalize upon agonist activation but ConA, a well-known
receptor-internalization blocker [35–38], only abolishes agonist-
mediated internalization ofα1A-AR.Whenwe analyzed the internaliza-
tion together to ERK phosphorylation kinetics elicited by either α1A- or
α1B-AR, we found that maximal α1A-AR internalization was achieved
5 min after PE stimulation but a sustained ERK activation located in
the cytosol and inhibited by β-arrestin 2 knockdown and ConAwas ob-
served evenwhen the receptorwasmaximally internalized. Conversely,
agonist induced internalization of the α1B-AR, by a mechanism that, in
our experimental conditions, is unaffected by β-arrestin 2 knockdown
or treatment with ConA, was almost maximal at 10 min but, at this
time, ERK1/2 phosphorylation had already returned to basal levels,
suggesting that the internalized receptor was not able to activate
ERK1/2. All these ﬁndings suggest that α1A-AR, when stimulated by
PE, internalizes via a ConA-sensitive mechanism responsible for the
late PKC-independent ERK activation and this relates to the anti-apoptotic activity of the α1A subtype. Thus, differences in the internali-
zationmechanisms lead to different intracellular signaling pathways for
each subtype, which could explain why anti-apoptotic activity,
could be exhibited only by the α1A subtype. In this regard, it has
been previously found that the α1B-subtype shows a stronger interac-
tion with β-arrestin than the α1A-AR [19]. Our results are compatible
with these previous observations. In our hands, the constitutive inter-
nalization of the α1B-subtype was inhibited by ConA, but the subse-
quent addition of the agonist gives a similar proﬁle of internalization
independent of the presence of ConA, suggesting that receptor-
internalization of the α1B-AR was, at this time, completed. Therefore,
it would be interesting to further study the different mechanisms of
internalization in order to establish why the α1A-AR, which shows a
weaker interaction with β-arrestin, elicits a late ERK1/2 activation
dependent on endosomic internalization, while the α1B-AR does not.
Little is known about the role of a differential ERK distribution in
the cell. Nuclear p-ERK substrates, particularly transcription factors,
have been extensively studied but cytoplasmic substrates have been
the object of less scrutiny. However, several examples suggest that
cytoplasmic ERK activity is important in cell viability and apoptosis
[40,41] and it has been established that the cyto-protective activity
of other GPCR as AT1A receptors is related to β-arrestin 2 dependent
activation of cytosolic ERK. In the same way, perinuclearly localized
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Fig. 7. Scheme depicting the different pathways involved in ERK1/2 phosphorylation by the three human α1-AR subtypes. PKC, protein kinase C.
2332 M. Perez-Aso et al. / Biochimica et Biophysica Acta 1833 (2013) 2322–2333α1A -ARs, but not α1B or α1D-AR, has been shown that exerts an
antiapoptotic and cardioprotective role in cardiomyocytes, which is
mediated by ERK activation [42].
On the other hand, it has been recently shown that the wild-type
and a genetic variant of the α1A-AR transactivate EGFR via a
β-arrestin-dependent mechanism [43]. The parallelism between this
mechanism and the β1-AR mediated EGFR transactivation, which
confers cardioprotection [44,45] suggests that EGFR transactivation
could be involved in the antiapoptotic and cardioprotective activity
of the α1A-subtype.
Therefore, previous evidences and present results strongly suggest
that the cytosolic-conﬁned pool of p-ERK activated by α1A-AR in a G
protein-independent β-arrestin dependent fashion, probably via
EGFR transactivation [43], is a prosurvival pathway relevant for
cardioprotection, and could explain the clinical evidence that chronic
use of non subtype selective α1 antagonists as doxazosin was associ-
ated with higher risk factor for coronary heart disease [46,47]. Future
work in the ﬁeld could be necessary to establish the exact role of
EGFR transactivation on the G protein-independent, β-arrestin
dependent retention of p-ERK in the cytoplasm elicited by α1A-AR
activation.
Previous studies have identiﬁed constitutive activity ofα1D-AR; that
is, activity in the absence of agonist stimulus [11,13–16]. In order to an-
alyze potential constitutive activation of ERK1/2, we compared basal
phosphorylation state in the cells transfected with eachα1-AR subtype.
As Supplemental Fig. 3 shows, α1D-AR-transfected cells showed the
highest phospho-ERK1/2 basal level and treatmentwithα1-antagonists
such as prazosin (PZ, a non selective α1 antagonist) and BMY 7378
(a selective α1D antagonist), decreased this basal ERK1/2 phosphoryla-
tion, thus conﬁrming that α1D-AR constitutively activates ERK1/2 and
that these compounds act as inverse agonists, as previously concluded
[11,13–16]. Unfortunately, we were not able to observe internalization
of α1D-AR using CypHer5 technology and the VSV-G-tagged receptor.
As previously described, α1D-AR is intracellularly distributed [12] andhas shown striking difﬁculties when attempts to detect it have been
made [48].Wehypothesize two reasonswhywewere not able to detect
VSV-G-tagged α1D-AR: ﬁrst, a CypHer-5-antiVSV-G-tagged receptor is
visible only in the acidic pH environment of an internalized endosome
[26], meaning that active internalization is needed to visualize the
receptor. If α1D-AR is predominantly intracellular it would not be
labeled by the antibody and detected by the CypHer5 dye. In fact, previ-
ous works strongly suggest that the α1D-AR is constitutively active
and, as a result, is localized to intracellular compartments involving
β-arrestin2 internalization [11]. Second, it is possible that the trafﬁcking
pattern of VSV-G-α1D-AR could bemodiﬁed by VSV-G-tagging, because
the characteristic distribution ofα1D-AR appears to be related to its long
N-terminal domain [49], where the VSV-G-tag is placed.
Additional experiments are required to clarify this point, as well as
the physiological meaning of both the constitutive and PE-induced
ERK1/2 phosphorylation mediated by the α1D-AR that is not depen-
dent on PKC activation and is restricted to the cytosol.5. Conclusions
The present study reveals that the three α1-AR subtypes present
different spatio-temporal patterns of ERKphosphorylation and receptor
internalization. Only α1A-AR elicits a late and sustained ERK phosphor-
ylation that is dependent on receptor-internalization and is restricted
to the cytosol. This late ERK activation may relate to the anti-
apoptotic-cardioprotective effect of α1A-AR.Acknowledgements
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